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Abstract
The most prevalent type of dementia is Alzheimer's disease (AD), which is currently incurable. Existing treatments for
Alzheimer's disease, such as acetylcholinesterase inhibitors, are only effective for symptom relief. Disease-modifying medications for Alzheimer's disease are desperately required, given the enormous burdens that the disease places on individuals
and communities. Phosphodiesterase (PDE) inhibitors are gaining a lot of attention in the research community because of
their potential in treating age-related cognitive decline. Cilostazol is a selective PDE III inhibitor used as antiplatelet agent
through cAMP response element-binding (CREB) protein phosphorylation pathway (cAMP/CREB). The neuroprotective
effect of cilostazol in AD-like cognitive decline in rats was investigated in this study. After 2 months of intraperitoneal
administration of 10 mg/kg aluminum chloride, Morris water maze and Y-maze (behavioral tests) were performed. After
that, histological and biochemical examinations of the hippocampal region were carried out. Aluminum chloride-treated rats
showed histological, biochemical, and behavioral changes similar to Alzheimer's disease. Cilostazol improved rats' behavioral and histological conditions, raised neprilysin level while reduced levels of amyloid-beta protein and phosphorylated
tau protein. It also decreased the hippocampal levels of tumor necrosis factor-alpha, nuclear factor-kappa B, FAS ligand,
acetylcholinesterase content, and malondialdehyde. These outcomes demonstrate the protective activity of cilostazol versus
aluminum-induced memory impairment.
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Introduction
Dementia is a major health issue, being correlated with
significant mortality and morbidity (Ballard et al. 2011).
Dementia affects the elderly in the overwhelming majority
of instances, producing age the most significant risk factor.
Dementias are categorized depending upon their underlying pathologies, which are largely determined by misfolded
proteins aggregate accumulation in neurons and glia, and
also in the extracellular matrix, in vulnerable brain regions
(Seeley et al. 2009).
The buildup of abnormally folded protein fragments,
including amyloid-beta (Aβ) and tau proteins, which form
amyloid plaques (Aβ plaques) and neurofibrillary tangles
(NFTs), consecutively, characterizes Alzheimer's disease
(AD) dementia (Pluta et al. 2013; Singh et al. 2013). Neprilysin (NEP) was first recognized as the major Aβ degrading enzyme utilizing biochemical approaches (Iwata et al.
2000). The NEP gene's deletion or NEP activity inhibition
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Materials and methods

was demonstrated to elevate Aβ levels in AD's mouse models (Eckman et al. 2006; Farris et al. 2007).
Numerous examinations initially indicated that in addition to Aβ plaques and NFTs, the brains of patients with
AD appeared proof of a long-term inflammatory reaction
(Tuppo and Arias 2005; Mrak and Griffin 2007). Inflammation in the brain appears to get dual function, acting as
a neuroprotective factor throughout an acute response but
becoming harmful as a chronic response develops (Kim and
Joh 2006). Drugs presently used to treat AD have restricted
advantages, so there is a necessity for a reliable treatments
that will not only supply symptomatic relief but also slow
the progression of the disease.
Phosphodiesterase inhibitors as cilostazol were reported
to improve cyclic guanosine monophosphate (cGMP) and/
or cyclic adenosine monophosphate (cAMP) signaling by
reducing these cyclic nucleotides’ degradation (Heckman
et al. 2015). As both cGMP and cAMP signaling are crucial
to various cellular functions, involving neuroprotection and
neuroplasticity, a clinical application of cilostazol for AD is
expected (Saito et al. 2016).
As a selective inhibitor of cAMP phosphodiesterase type
III, cilostazol elevated levels of cAMP stimulate protein
kinase A, ending in platelet aggregation inhibition (Gresele
et al. 2011). It also has several pharmacological actions,
such as anti-oxidative, anti-apoptotic, and anti-inflammatory
impacts in the brain (Hong et al. 2006). It is also recognized
to decrease Aβ accumulation and to enhance brain function in an experimental model of AD (Park et al. 2011), and
therefore, it appeared interesting to study the possible protective impacts of cilostazol on aluminum-induced memory
impairment in rats.

Fig. 1  Graphical illustration
of the experimental design.
ALCL3, aluminum chloride

Animals
Male adult Wistar rats weighting between 130 and 150 g
were used. Animals were maintained at stable surroundings: 12:12 h light/dark cycle, humidity (60 ± 10%), and
temperature (23 ± 1 °C). Before the beginning of the
experiments, an adaptation period of 1 week was given
for rats to acclimatize with the new conditions, and they
were fed rat food and water ad libitum.

Chemicals and drugs
Cilostazol (Pletal®) was bought from Otsuka Pharmaceutical Co., Cairo, Egypt, and aluminum chloride (ALCL3)
was bought from Sigma-Aldrich, St. Louis, MD, USA.
Chemicals used in the present work were of highly pure
and of excellent analytical grade.

Experimental design and treatment protocol
As described in Fig. 1, four groups of animals (10 rats
per group) were required, Group 1 (Control group): rats
were given saline, ip, once per day for 60 days. Group 2
( ALCL3 group): rats were given A
 LCL3 (10 mg/kg, ip)
once per day for 60 days. Group 3 (cilostazol group): rats
were given cilostazol (50 mg /kg, po) once per day for
60 days. Group 4 ( ALCL3 + cilostazol group): rats were
given ALCL3 (10 mg/kg, ip) and cilostazol (50 mg /kg,

Daily administration of Aluminum and Cilostazol for 60 days

Morris water maze
Training

Days

1 2 3 4 5

……….………………………………

Group 1: Control
Group 2: ALCL3
Group 3: Cilostazol
Group 4: ALCL3 + Cilostazol
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po) once per day for 60 days. Four days before the end
of the experiment (day 56), rats were trained on Morris
water-maze test for 4 consecutive days. At the end of the
experiment (day 60), Morris water-maze probe test was
done together with Y-maze spontaneous alternation test.

minutes. To get rid of any residual odors, we cleaned arms
well between each animal. When a rat puts his hind paws
totally inside one of the three arms, so this was counted as
a complete arm entry. An alternation was defined as a triad
that contains the three letters (ABC, CAB, etc.). Spontaneous alternation percentage (SAP) was obtained from both
total arm entries and number of alternations using the following equation:

Behavioral tests
Morris water maze test

SAP(%) = ((number of alternations)∕(total arm entries − 2)) × 100.

Morris water-maze test was used to assess spatial learning
and memory. The maze consists of rounded container of
60 cm height and 150 cm diameter, and contains water to a
depth of 40 cm of temperature 27 ± 1 °C. The container is
splitted into four partitions (quadrants) and a portable Plexiglass stand of 8 cm in diameter located inside a specified
quadrant. For 4 consecutive days, rats were trained in the
maze twice daily for 120 s, where they were allowed to find
the stand in the specific quadrant by their own in every time,
once the rat finds the stand it was permitted to stay on it for
10 s, however, if it failed to find the stand within this 120 s, it
was permitted to stay on it for 30 s. The probe test was done
on the fifth day, we removed the stand and each animal was
allowed to swim freely in the container for 120 s, during the
120 s, we calculate the index of retrieval which is the time
each rat stayed in the target quadrant (i.e., the quadrant in
which the stand was there) (Morris 1984; Kim et al. 2012).

Tissue sampling
Tissue sampling was done on day 61 of the experiment
(24 h following behavioral experiments). Under anesthesia,
animals were euthanized by decapitation, and brains were
then separated quickly to collect hippocampai which were
freezed at − 80 °C. For biochemical analysis, the collected
hippocampai were homogenized (10% w/v) in phosphate
buffer (pH 7.4) to obtain the homogenate. In addition, from
each group, two rats were selected randomly to obtain their
whole brains, which were placed in formalin (10%) for histopathological assessment.

Biochemical analysis
Hippocampal contents of neprilysin, phosphorylated tau
(P-tau), amyloid-beta 1–42 (Aβ1−42), FAS ligand (FAS-L),
tumor necrosis factor-alpha (TNF-α), nuclear factor-kappa B
(NF-κB), malondialdehyde (MDA), and acetylcholinesterase
content (AChE) were detected using the ELISA technique.

Y‑maze spontaneous alternation test
Y-maze test was done as reported previously (Wall and
Messier 2002). The maze consists of three identical arms
(A, B, and C), there are equal angles in between them, each
arm is 35 cm in height, 40 cm in length, and 12 cm in width.
At the end of one of the three arms, we put animals, and
then, they were allowed to move freely in the maze for five

Rats’ whole brains were placed in formalin (10%) for 24 h.
Brains were dehydrated and washed by alcohol, then cleared
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Fig. 2  Effect of cilostazol on
behavior of rats in Morris water
maze (a) and Y-maze (b) tests
in control and A
 LCL3-treated
rats. Values are displayed as
mean ± SEM (n = 10). *Significantly different from control
group (p < 0.05), @significantly
different from ALCL3 group
(p < 0.05)

Histopathological examination
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in xylene, and finally fixed in paraffin in hot air oven at 56 °C
for 24 h. Brain sections (thickness: 3-μm) were stained using
hematoxylin and eosin to be ready for examination under
a light microscope provided with a camera. Samples histopathological examination and handling were performed
by a specialist who did not know samples nature to avoid
any bias.

Cilostazol alone showed no effect on levels of neprilysin,
Aβ1–42 and p-tau in comparison with control rats, while its
administration to A
 LCL3-treated rats increased neprilysin
content (1.3-fold) and decreased levels of Aβ1–42 (28%)
and p-tau (30%) of that in A
 LCL3 group.

Statistical analysis
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One-way analysis of variance (ANOVA) were used to compare between different groups, and for multiple comparisons,
Tukey Kramer’s test was used. GraphPad Prism 6.0 (GraphPad Software, San Diego, CA, USA) was used for statistical
analysis. Values were displayed as mean ± SEM, at p < 0.05
as the minimum level of significance.

Morris water maze test
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Aluminum chloride (ALCL3) decreased hippocampal content of neprilysin to 50% (Fig. 3a) and raised hippocampal
contents of both Aβ 1–42 by 3.5-fold (Fig. 3b) and p-tau
by 3.2-fold (Fig. 3c) when compared to control group.
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Effect of cilostazol on hippocampal content of amyloid
beta1–42 (Aβ1−42), phosphorylated tau (p‑tau),
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Spontaneous alternation percentage (SAP) decreased significantly in ALCL3 group when compared to that in control group. Cilostazol administration to normal rats made
no significant difference in SAP in comparison to that
in control group. Cilostazol increased SAP when given
to ALCL3-treated rats when compared to A
 LCL3 group
(Fig. 2b).
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Time spent by rats treated with aluminum chloride (ALCL3)
in target quadrant was less than that in control rats. Cilostazol administration to normal rats did not change their behavior in Morris test when compared to control group, while its
administration to ALCL3-treated rats increased time spent
by rats in target quadrant to 139.82% of that in ALCL3 group
(Fig. 2a).

Fig. 3  Effect of cilostazol on hippocampal content of neprilysin (a),
amyloid beta1-42 (Aβ1–42, b), and phosphorylated tau (p-tau, c) in
control and A
 LCL3-treated rats. Values are displayed as mean ± SEM
(n = 10). *Significantly different from control group (p < 0.05), @significantly different from ALCL3 group (p < 0.05)
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normal rats showed no change in the previous parameters,
while when administered to rats treated with ALCL3, it
significantly decreased them, NF-κB (21%), TNF-α (27%),
and FAS-L (21%) of that in ALCL3 group.
Effect of cilostazol on hippocampal content
of malondialdehyde (MDA) in control and ALCL3‑treated
rats
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Aluminum chloride administration raised hippocampal content of MDA by 1.9-fold (Fig. 5). Cilostazol had no effect
on MDA level when administered alone, but when given
to ALCL3-treated rats, it lowered MDA to 72% of that in
ALCL3 group.
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Aluminum chloride administration raised hippocampal content of AChE by 3.4-fold (Fig. 6) than when compared to
control group. Administration of cilostazol alone to normal
rats showed no significant effect in comparison to control
group, but when given to A
 LCL3-treated rats, it lowered
AChE content to 24% of that in ALCL3 group.

Histopathological analysis
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Effect of cilostazol on hippocampal acetylcholinesterase
(AChE) content in control and ALCL3‑treated rats

Fig. 4  Effect of cilostazol on hippocampal content of nuclear factorkappa B (NF-κB, a), tumor necrosis factor-alpha (TNF-α, b), and
FAS ligand (FAS-L, c) in control and ALCL3-treated rats. Values
are displayed as mean ± SEM (n = 10). *Significantly different from
control group (p < 0.05), @ significantly different from A
 LCL3 group
(p < 0.05)

Effect of cilostazol on hippocampal content of nuclear
factor‑kappa B (NF‑κB), tumor necrosis factor‑alpha
(TNF‑α), and FAS ligand (FAS‑L) in control and ALCL3‑treated
rats
Administration of A LCL 3 for 60 days significantly
increased levels of NF-κB by 4.2-fold (Fig. 4a), TNF-α
by 3.4-fold (Fig. 4b), and FAS-L by 3.7-fold (Fig. 4c) in

Histopathological assessment of the hippocampus also supported the biochemical findings of the present study. Microscopic examination of sections from control group revealed
normal organization and structure of neuronal cells with
normal appearance of the hippocampus (Fig. 7a). Sections
from rats treated with A
 LCL3 revealed neurodegenerative
alterations, necrosis, and abnormal appearance of the neurons and their nuclei (Fig. 7b). Cilostazol administration to
normal rats revealed normal appearance of the hippocampus
(Fig. 7c). Administration of cilostazol to A
 LCL3-treated rats
ameliorated the observed neurodegenerative pathological
changes that occurred in ALCL3-treated rats’ hippocampus
(Fig. 7d).
Cilostazol alleviated the neurodegenerative pathological
alterations that appeared in ALCL3-treated rats hippocampus. The above micrographical photos (H&E × 400) display
rats’ hippocampal sections collected on day 61 of this work. a
Control group: revealed normal organization and structure of
neuronal cells with normal appearance of the hippocampus. b
ALCL3 group: revealed abnormal appearance of the neurons
and their nuclei, necrosis and neurodegenerative changes. c
Cilostazol group: showed normal appearance of the hippocampus. d AlCl3 + cilostazol group: showed alleviation of
the neurodegenerative pathological changes that observed in
ALCL3-treated rats hippocampus.
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Fig. 5  Effect of cilostazol on hippocampal content of malondialdehyde (MDA) in control and A
 LCL3-treated rats. Values are displayed
as mean ± SEM (n = 10). *Significantly different from control group
(p < 0.05), @significantly different from A
 LCL3 group (p < 0.05)
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Fig. 6  Effect of cilostazol on hippocampal acetylcholinesterase
(AChE) content in control and A
 LCL3-treated rats. Values are displayed as mean ± SEM (n = 10). *Significantly different from control group (p < 0.05), @significantly different from A
 LCL3 group
(p < 0.05)

Discussion
The current study focuses on the potential protective role
of cilostazol, a selective phosphodiesterase III inhibitor,
on aluminum-induced memory dysfunction. Behavioral,
biochemical, and histopathological alterations following
aluminum chloride administration alone or with cilostazol
were evaluated.
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Phosphodiesterases (PDEs) are enzymes that hydrolyze phosphodiester bonds to break down cyclic guanosine monophosphate (cGMP) and/or cyclic adenosine
monophosphate (cAMP). As a result, the intracellular levels of these ubiquitous second messengers are regulated.
PDE inhibitors could be a powerful tool for influencing
second messengers related to learning, memory, and mood
(Hebb and Robertson 2007; Houslay et al. 2007).
In behavioral tests (Y-maze and Morris water maze,
MWM), cilostazol was found to have a beneficial effect on
memory and learning deficits caused by aluminum. Previous studies have shown that high levels of aluminum in
the brain have an effect on long-term potentiation, which
is thought to be the primary physiological foundation for
learning and memory (Llansola et al. 1999; Shuchang
et al. 2008). This study is in harmony with the other studies that showed learning and memory insufficiency following treatment with aluminum in MWM (Rani et al.
2015; Justin Thenmozhi et al. 2016; Abdel-Zaher et al.
2017) and Y-maze test (Safar et al. 2016; Alawdi et al.
2017). Other studies showed improved rats’ behavior in
MWM (Watanabe et al. 2006; Lee et al. 2007; Kumar et al.
2015; Kim et al. 2016) and Y-maze (Hiramatsu et al. 2010;
Maki et al. 2014) after treatment with cilostazol. PDE
inhibitors have been investigated as a potential medicative intervention for cognitive disorders (Blokland et al.
2006; Reneerkens et al. 2009) via their cyclic nucleotides
improving property. Cilostazol elevates cAMP in vascular
cells, and has multiple impacts on the vasculature including anti-oxidation, vasodilatation, anti-inflammation, and
smooth muscle cell regulation (Chen et al. 2011). The rise
in cAMP activates protein kinase A, which then phosphorylates the cAMP response element-binding (CREB) protein. Phosphorylation of CREB stimulates numerous target
genes, which activate new protein synthesis, thereby reinforces the existing synaptic connections and establishing
new ones responsible for memory consolidation (Benito
and Barco 2010). As well as, activation of CREB promotes the gene expression of neuroprotective molecules
as brain-derived neurotrophic factor (BDNF) (Watanabe
et al. 2006; Nishimura et al. 2007; Miyamoto et al. 2010).
In the present work, hippocampal contents of Aβ 1-42
and p-tau were increased together with reduced level of
neprilysin (Aβ protein degrading enzyme) in aluminum
chloride-treated rats. These outcomes are in accordance
with Alawdi et al. (2017). Cilostazol decreased hippocampal content of Aβ1−42 and p-tau, while elevated neprilysin content in aluminum chloride-treated rats. Dramatic
decrease in tau phosphorylation and Aβ accumulation with
subsequent improvement in spatial memory and learning
in Aβ25–35-injected mice after medication with cilostazol
were observed (Tsukuda et al. 2009). Moreover, it was
shown that cilostazol significantly suppressed both Aβ1–42

Phosphodiesterase (PDE) III inhibitor, Cilostazol, improved memory impairment in aluminum…
Fig. 7  A photomicrograph of
brain tissue section of rat from
control and ALCL3-treated rats

and Aβ1–40 aggregation and reduced Aβ production and tau
phosphorylation in vitro (Lee et al. 2014; Maki et al. 2014;
Schaler and Myeku 2018; Shozawa et al. 2018).
The accumulation of Aβ protein in Alzheimers disease (AD) animal models results in suppression of CREBmediated intracellular signaling pathways and impedes longterm potentiation (Puzzo et al. 2006). Cilostazol reverses this
effect by the activation of protein kinase A which mediates
CREB phosphorylation, and impairs the Aβ-synthesizing
enzymes expression comprising β- and γ-secretase that
results in decreased Aβ generation (Arendash et al. 2009).
Furthermore, cilostazol-mediated cAMP might improve
α-secretase activity, resulting in reduced Aβ generation
(Maki et al. 2014) (Fig. 8).
Elevated hippocampal acetylcholinesterase (AChE) content was observed after aluminum chloride injection. Elevated brain AChE activity may be considered as a marker
of cognitive dysfunction (Xiao et al. 2012). Other findings
suggested that administration of aluminum increased AChE
in mouse brain (Kaizer et al., 2005; Kumar et al., 2011).
Aluminum was found to affect AChE peripheral sites and
modify its secondary structure, which results in inducing its
activity (Zatta et al. 1994). Cilostazol overturned the rise in
AChE content in aluminum chloride-treated rats, this result
demonstrated cilostazol's ability to mitigate cognitive dysfunction associated with AD. Kumar et al. (2015) detected
that cilostazol significantly prevented streptozotocin-induced
raise in AChE activity.

Inflammation is thought to be a key factor in AD, it triggers nervous system's defense mechanism through stimulation of microglia and astrocytes, and this ends in releasing of inflammatory cytokines and oxy radicals (Minghetti
et al. 2005; Moynagh 2005). Hickman et al. (2008) noticed
that the levels of insulin-degrading enzyme, neprilysin, and
matrix metalloproteinase 9 (Aβ protein degrading enzymes)
were dramatically decreased in older mice with the proinflammatory cytokines’ concomitant upregulation. FAS
and FAS ligand (FAS-L) were found to be involved in Aβ
protein-induced neuronal death (Millet et al. 2005). Aβ protein induces FAS-L expression via a Jun N-terminal kinase
(JNK3) dependent pathway (Morishima et al. 2001).
Nuclear factor-kappa B (NF-κB) is a transcription factor
that controls the production of multiple pro-inflammatory
factors in inflammatory responses (Hayden and Ghosh
2004). Normally, NF-κB is binded to its biological inhibitor (inhibitor of kappa B, IκB) in the cytoplasm. IκBs are
phosphorylated and then degraded by the IκB kinase (IKK)
complex in response to inflammatory stimuli, resulting in
free NF-κB dimmers' release (Zaky et al. 2013), displaying
the DNA-binding capacity and transactivation potentials, as
a result, inflammatory cytokine genes such as IL-6 and IL-8
will be expressed (Karin 2009; Brasier 2010; McFarland
et al. 2013). The heterodimer of the p65 and p50 subunits
is the most studied form of NF-κB that acts as a powerful
gene transcription activator (Schmitz and Baeuerle 1991).
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Fig. 8  Diagram illustrating the
protective actions of cilostazol
against aluminum-induced
memory impairment
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The present study demonstrated that cilostazol reduced
the levels of FAS-L, tumor necrosis factor-alpha (TNF-α),
and NF-κB. Cilostazol exerted anti-inflammatory activities
in microglial cells and diabetic rats (Wang et al. 2008; Jung
et al. 2010) by suppressing inflammatory cytokine generation and signaling (Jung et al. 2010). It also reduced raised
TNF-α level and decreased the apoptosis level and cell
death (Kim et al. 2002). Watanabe et al. (2006) revealed
that cilostazol's neuroprotective role might be manifested
via its anti-apoptotic impact through the CREB phosphorylation signaling pathway and subsequent stimulation of Bcl-2.
Also, cilostazol reduced the expression of the proapoptotic
protein Bax and the stimulation of apoptosis effector caspases (Oguchi et al. 2017).
Although AD pathogenesis is complex, oxidative impairment may be one of the initial events in its etiology and progression (Sultana and Butterfield 2010; Tayler et al. 2010).
The hippocampal region is affected more from oxidative
stress in comparison with other brain regions (Miller and
O'Callaghan 2005; Yargicoglu et al. 2007). One of the most
common consequences of free radical-mediated injury is
lipid peroxidation, which degrades membranes directly and
produces a variety of secondary products, such as aldehydes
like malondialdehyde (MDA) (Slater 1984). Lipid peroxidation up-regulates β-secretase expression in vivo (Chen
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et al. 2008), suggesting that lipid peroxidation avoidance is
a critical initial event in amyloidogenesis reduction in AD.
In this study, we observed a significant amount of oxidative
stress manifested itself in the form of elevated lipid peroxidation. Disruption of Golgi apparatus, reduction of synaptic
vesicles, and reduced axonal mitochondrial turnover could
all contribute to significant oxidative stress after aluminum
administration (Bharathi et al. 2006). A raise in MDA level
was noticed in rats' entire brains (Lakshmi et al. 2015), rats'
hippocampi (Abdel-Zaher et al. 2017), and mice hippocampi
(Jangra et al. 2015) after aluminum administration.
Cilostazol decreased MDA level when administered to
aluminum chloride-treated rats. Several studies observed
that cilostazol significantly reduced lipid peroxidation in
the brain in different experimental models (Hiramatsu et al.
2010; Lee et al. 2010; Sahin et al. 2011; Kumar et al. 2015).
PDE III inhibitors have potent anti-oxidative characteristics (Park et al. 2007; Genovese et al. 2011). Increases in
intracellular cyclic nucleotides like cAMP have also been
shown to reduce reactive oxygen generation, oxidative
stress, and subsequent development of cellular dysfunction
(Milani et al. 2005). Cilostazol inhibits oxidative stress, and
thus suppresses Aβ1–42-induced neurotoxicity, as evidenced
by decreased reactive oxygen species accumulation and
elevated expression of the anti-oxidant enzyme superoxide
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dismutase (Oguchi et al. 2017). Moreover, cilostazol may
reduce cognitive deficits by suppressing the early accumulation of lipid peroxidation products, as well as the subsequent
inflammatory responses, such as the reduction of apoptotic
cells (Watanabe et al. 2006).

Conclusion
We can conclude from these findings that cilostazol reduced
aluminum-induced cognitive decline through a variety of
mechanisms, such as its anti-inflammatory, anti-oxidant, and
anti-apoptotic properties via the cAMP/CREB phosphorylation pathway.
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